Prophylaxis with palivizumab against respiratory syncytial virus infection in infants with congenital heart disease—who should receive it?
Jan SunnegårdhVolume:
95
Year:
2006
Language:
english
Pages:
3
DOI:
10.1111/j.1651-2227.2006.tb02249.x
File:
PDF, 57 KB
english, 2006